American Renal Associates

The firm used a joint-venture model in which nephrologists hold equity stakes in the individual dialysis clinics where they serve as medical directors. ARA provided centralized management, billing, and compliance infrastructure. This design gave physicians both governance rights and economic exposure tied to their specific facility's performance.

Following the Nautic Partners acquisition in 2019, strategic decisions shifted to the private equity sponsor. Chairman and co-founder Joseph Carlucci remained involved post-transaction, while President Syed Kamal oversaw day-to-day operations. Nautic's healthcare team, led by Chris Corey and Scott Hilinski, assumed board-level governance.

DaVita and Fresenius predominantly own and operate clinics outright, employing or contracting physicians on professional-services agreements. ARA's model made physicians minority equity partners in the specific clinics they oversee, creating a direct financial link between clinical operations and practice-level returns. This structure was designed to reduce physician turnover and strengthen local market relationships.

No. As a single corporate entity (and later a private equity portfolio company), ARA deployed capital exclusively into clinic-level joint ventures and operational infrastructure. There is no evidence of the firm operating as a fund, acting as a limited partner, or managing third-party capital.

ARA concentrated its clinic footprint in the southeastern and southwestern United States, with Texas and Florida representing the largest density. The firm also operated clusters in Mid-Atlantic states and maintained a revenue-cycle center in Tennessee. All facilities served exclusively domestic patients under Medicare and commercial insurance reimbursement frameworks.

Since the take-private in 2019, ARA operates as a privately held portfolio company of Nautic Partners, a Providence, Rhode Island-based middle-market private equity firm. Nautic installed a board comprising partners from the firm and ARA operating executives, replacing the public-company governance structure that existed from the 2016 IPO through early 2019.

ARA was always an operating company — first physician-founded, then publicly listed, and most recently private equity-backed. It does not manage a family's wealth, nor does it operate as a multi-family office. The firm's capital was enterprise revenue reinvested into clinic development, not a pool of inherited or legacy wealth.